Cancer of the Common Hepatic Bile Ducts—Palliative Radiotherapy

Green, Nathan; Mikkelsen, William P.; Kernen, Jules A.

doi:10.1148/109.3.687

Cited by 50 publications

(9 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Reports presented by radiologists have shown that external radiation may prolong survival rates in these patients [20,34].…”

Section: Radiotherapymentioning

confidence: 99%

See 1 more Smart Citation

Current Status in the Management of Proximal Bile Duct Carcinoma

Camprodon¹

1986

Eur Surg Res

View full text Add to dashboard Cite

The confluence of the biliary duct constitutes the most common location of the bile duct neoplasms. Resection of the tumor is the only procedure which has met with longterm survival rates (more than 5 years). An enhanced exposure of the tumor in surgical intervention contributes to increasing the number of resectable cases. The transhepatic approach through the principal incision offers the best possibility to explore the tumors of the proximal bile duct confluence, using this approach the resection rate is higher than that of other routes. The surgical management of confluence biliary duct carcinoma can be curative if the diagnosis is made in early stages of the disease and if at that time resection is possible.

show abstract

“…Reports presented by radiologists have shown that external radiation may prolong survival rates in these patients [20,34].…”

Section: Radiotherapymentioning

confidence: 99%

“…Reports indicate that cobaltotherapy is safe; however, the amount of this therapy necessary to cause destruction of the cancer cells results in fibrosis of the bile duct [20], It remains to be seen how effective radio therapy is. Nowadays, many authors ques tion the benefits of radiation therapy with its various possibilities.…”

Section: Radiotherapymentioning

confidence: 99%

Current Status in the Management of Proximal Bile Duct Carcinoma

Camprodon¹

1986

Eur Surg Res

View full text Add to dashboard Cite

show abstract

“…Radiotherapy for cholangiocarcinoma yields minimal prolongation of survival, and some controversy remains regarding its efficacy. As a result of this insufficiency to control the tumor volume, [7][8][9][10][11][12][13][14][15][16][17] there is high incidence of stent occlusion caused by tumor ingrowth or overgrowth. 6,18 The stent patency period is as short as 3 to 6 months, and mean survival varies from 6 to 12 months.…”

mentioning

confidence: 99%

“…6,18 The stent patency period is as short as 3 to 6 months, and mean survival varies from 6 to 12 months. [8][9][10][11][12][13][14]16,19 Because death is usually caused by locoregional diseases rather than distant metastases, 13,20 local control of the tumor is important in prolonging the survival periods of these patients.…”

mentioning

confidence: 99%

A Study of Carboplatin–Coated Tube for the Unresectable Cholangiocarcinoma

et al. 2000

View full text Add to dashboard Cite

Most cases of cholangiocarcinoma have reached an unresectable stage by the time they are discovered despite significant progress of diagnostic modalities. Many of these patients with obstructive jaundice are often treated by biliary drainage using stents to relieve the jaundice. However, the stent patency period is as short as 3 to 9 months because of tumor ingrowth or overgrowth, and mean survival is at most 12 months. Therefore, both continuous relief of obstructive jaundice and local control of the tumor are required in the treatment for advanced cholangiocarcinoma. In this investigation, we developed a new percutaneous transhepatic biliary drainage tube coated with carboplatin (carboplatin-coated tube; CCT). CCT continuously released a fixed amount of carboplatin for 4 weeks and showed an antitumor effect on human cholangiocarcinoma cell line HuCC-T1 in vitro. When CCT was embedded in subcutaneous tumor inoculated in nude mice, a significant reduction of tumor size with no apparent damage to normal adjacent tissue was observed. On the basis of these studies, 5 patients with inoperable cholangiocarcinoma were treated with CCT for 4 weeks. Overall efficacy rate of 5 patients with cholangiocarcinoma was 60% (partial response in 3 and no change in 2). No apparent side effect was observed in these patients. Thus, CCT may provide a new treatment modality for this disease. Randomized controlled trials comparing CCT therapy with palliative stenting are required to confirm these results. (HEPATOLOGY 2000;32:916-923.)

show abstract

“…In den letzten Jahren gewinnt die Bestrahlungstherapie der malignen Gallengangs verschlüsse zunehmend an Bedeutung. Die anfänglich ange wandte perkutane Strahlentherapie mußte wegen der Gefahr lokaler und systemischer Nebenwirkungen auf 40-50 Gy beschränkt bleiben [9,10,14,20,21,29,31]. Die Neuentwick lung einer intraluminalen Bestrahlung mit Iridium oder Radium bot die Möglichkeit, hohe Strahlendosen in das Zen trum des Tumors zu bekommen [3,7,8,12,17,22,23,30].…”

unclassified

Kombinierte intraduktale und perkutane Radiotherapie bei maligner Gallenwegsobstruktion mit anschließender prothetischer Versorgung

Brambs¹,

Freund²,

Bruggmoser³

et al. 1987

Oncol Res Treat

View full text Add to dashboard Cite

Die Strahlentherapie hat beim inoperablen malignen Verschlußikterus das Ziel, die Überlebenszeit gegenüber der palliativen Drainage zu verlängern. Bevorzugt wird eine Kombination einer intrakavitären Brachytherapie über eine perkutantranshepatische Drainage (30–40 Gy in 1 cm Abstand) mit einer perkutanen Pendelfeldbestrahlung (30–40 Gy). Diese Kombination erlaubt hohe lokale Tumordosen bei einem relativ großen Bestrahlungsvolumen. Nach Abschluß der Radiotherapie wird die PTD gegen eine dicklumige Prothese (14 F) ausgewechselt.

show abstract

Cancer of the Common Hepatic Bile Ducts—Palliative Radiotherapy

Cited by 50 publications

References 4 publications

Current Status in the Management of Proximal Bile Duct Carcinoma

Current Status in the Management of Proximal Bile Duct Carcinoma

A Study of Carboplatin–Coated Tube for the Unresectable Cholangiocarcinoma

Kombinierte intraduktale und perkutane Radiotherapie bei maligner Gallenwegsobstruktion mit anschließender prothetischer Versorgung

Contact Info

Product

Resources

About